File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Association between the TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms and gastric cancer: A case-control study

TitleAssociation between the TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms and gastric cancer: A case-control study
Authors
KeywordsClinicopathological characteristics
Transforming growth factor-ß
Polymorphism
Gastric cancer
Issue Date2011
Citation
Oncology Letters, 2011, v. 2, n. 2, p. 371-377 How to Cite?
AbstractThe transforming growth factor-α (TGFβ) pathway plays an important role in various types of human cancer. However, the role of TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms in gastric cancer is controversial. We aimed to investigate the associations between these polymorphisms and gastric cancer susceptibility, clinicopathological parameters and survival. A case-control study was conducted in 1,010 gastric cancer patients and 1,500 healthy controls. Genotypes were determined by PCR-restriction fragment length polymor¬phism and DNA sequencing. Compared with the TT genotype, the TGFB1 -509 C allele (CT/CC) was significantly associated with a reduced risk of gastric cancer (OR, 0.71; 95% CI, 0.58¬0.87; P=0.001) and certain subtypes of gastric cancer including intestinal type (OR, 0.70; 95% CI, 0.57-0.87; P=0.001), poorly differentiated (OR, 0.67; 95% CI, 0.54-0.85; P=0.001) and stage TNM III+IV (OR, 0.73; 95% CI, 0.58-0.92; P=0.008). Compared with the TGFBR2 -875 GG genotype, carriers of the A allele (AA/AG) had a significantly decreased gastric cancer risk (OR, 0.58; 95% CI, 0.62-0.91; P<0.001). A combination of the TGFB1 -509 C and TGFBR2 -875 A alleles was associated with a further decreased risk of gastric cancer (OR, 0.42; 95% CI, 0.32-0.57, P<0.001). No significant correlation was observed between polymorphisms and survival of gastric cancer patients. Our results suggest that both the TGFB1 -509 and TGFBR2 -875 polymorphisms contribute to a decreased gastric cancer risk. The TGFB1 -509 polymorphism affects certain subtypes of gastric cancer according to clinicopathological parameters. A combination of the TGFB1 -509 C and TGFBR2 -875 A alleles conferred a further decreased gastric cancer risk. These findings provide clues to the biological mechanisms that under¬line tumor heterogeneity.
Persistent Identifierhttp://hdl.handle.net/10722/207049
ISSN
2015 Impact Factor: 1.482
2015 SCImago Journal Rankings: 0.626

 

DC FieldValueLanguage
dc.contributor.authorXu, Lixia-
dc.contributor.authorZeng, Zhirong-
dc.contributor.authorChen, Bin-
dc.contributor.authorWu, Xiaoqin-
dc.contributor.authorYu, Jun-
dc.contributor.authorXue, Ling-
dc.contributor.authorTian, Linwei-
dc.contributor.authorWang, Yiming-
dc.contributor.authorChen, Minhu-
dc.contributor.authorSung, Joseph-
dc.contributor.authorHu, Pinjin-
dc.date.accessioned2014-12-09T04:31:18Z-
dc.date.available2014-12-09T04:31:18Z-
dc.date.issued2011-
dc.identifier.citationOncology Letters, 2011, v. 2, n. 2, p. 371-377-
dc.identifier.issn1792-1074-
dc.identifier.urihttp://hdl.handle.net/10722/207049-
dc.description.abstractThe transforming growth factor-α (TGFβ) pathway plays an important role in various types of human cancer. However, the role of TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms in gastric cancer is controversial. We aimed to investigate the associations between these polymorphisms and gastric cancer susceptibility, clinicopathological parameters and survival. A case-control study was conducted in 1,010 gastric cancer patients and 1,500 healthy controls. Genotypes were determined by PCR-restriction fragment length polymor¬phism and DNA sequencing. Compared with the TT genotype, the TGFB1 -509 C allele (CT/CC) was significantly associated with a reduced risk of gastric cancer (OR, 0.71; 95% CI, 0.58¬0.87; P=0.001) and certain subtypes of gastric cancer including intestinal type (OR, 0.70; 95% CI, 0.57-0.87; P=0.001), poorly differentiated (OR, 0.67; 95% CI, 0.54-0.85; P=0.001) and stage TNM III+IV (OR, 0.73; 95% CI, 0.58-0.92; P=0.008). Compared with the TGFBR2 -875 GG genotype, carriers of the A allele (AA/AG) had a significantly decreased gastric cancer risk (OR, 0.58; 95% CI, 0.62-0.91; P<0.001). A combination of the TGFB1 -509 C and TGFBR2 -875 A alleles was associated with a further decreased risk of gastric cancer (OR, 0.42; 95% CI, 0.32-0.57, P<0.001). No significant correlation was observed between polymorphisms and survival of gastric cancer patients. Our results suggest that both the TGFB1 -509 and TGFBR2 -875 polymorphisms contribute to a decreased gastric cancer risk. The TGFB1 -509 polymorphism affects certain subtypes of gastric cancer according to clinicopathological parameters. A combination of the TGFB1 -509 C and TGFBR2 -875 A alleles conferred a further decreased gastric cancer risk. These findings provide clues to the biological mechanisms that under¬line tumor heterogeneity.-
dc.languageeng-
dc.relation.ispartofOncology Letters-
dc.subjectClinicopathological characteristics-
dc.subjectTransforming growth factor-ß-
dc.subjectPolymorphism-
dc.subjectGastric cancer-
dc.titleAssociation between the TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms and gastric cancer: A case-control study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.3892/ol.2011.249-
dc.identifier.scopuseid_2-s2.0-79551623761-
dc.identifier.volume2-
dc.identifier.issue2-
dc.identifier.spage371-
dc.identifier.epage377-
dc.identifier.eissn1792-1082-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats